Revolutionizing drug delivery: The power of stimulus-responsive nanoscale systems
S Hu, R Zhao, Y Shen, B Lyu - Chemical Engineering Journal, 2024 - Elsevier
In recent years, the rapid evolution of nanotechnology has led researchers to increasingly
concentrate on the creation of multifunctional and controllable intelligent drug delivery …
concentrate on the creation of multifunctional and controllable intelligent drug delivery …
[HTML][HTML] Harnessing beta cell regeneration biology for diabetes therapy
S Bourgeois, S Coenen, L Degroote, L Willems… - Trends in Endocrinology …, 2024 - cell.com
The pandemic scale of diabetes mellitus is alarming, its complications remain devastating,
and current treatments still pose a major burden on those affected and on the healthcare …
and current treatments still pose a major burden on those affected and on the healthcare …
MicroRNA-221-3p inhibits the inflammatory response of keratinocytes by regulating the DYRK1A/STAT3 signaling pathway to promote wound healing in diabetes
K Hu, L Liu, S Tang, X Zhang, H Chang… - Communications …, 2024 - nature.com
Diabetic foot ulcer (DFU), a serious complication of diabetes, remains a clinical challenge.
MicroRNAs affect inflammation and may have therapeutic value in DFU. Here, we find that …
MicroRNAs affect inflammation and may have therapeutic value in DFU. Here, we find that …
Serum from pregnant donors induces human beta cell proliferation
KR Sylvester-Armstrong, CF Reeder, A Powell… - Islets, 2024 - Taylor & Francis
Pancreatic beta cells are among the slowest replicating cells in the human body and have
not been observed to increase in number except during the fetal and neonatal period, in …
not been observed to increase in number except during the fetal and neonatal period, in …
An shRNA screen in primary human beta cells identifies the serotonin 1F receptor as a negative regulator of survival during transplant
Islet transplantation can cure type 1 diabetes, but peri-transplant beta cell death limits this
procedure to those with low insulin requirements. Improving human beta cell survival or …
procedure to those with low insulin requirements. Improving human beta cell survival or …
Htr1f antagonists for improvement of beta cell survival and function
G Ku - US Patent App. 18/271,588, 2024 - Google Patents
KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR, 9R)-N-[(2S)-1-hydroxybutan-2-yl]-4, 7-dimethyl-
6, 6a, 8, 9-tetrahydroindolo [4, 3-fg] quinoline-9-carboxamide Chemical class C1= CC (C= 2 …
6, 6a, 8, 9-tetrahydroindolo [4, 3-fg] quinoline-9-carboxamide Chemical class C1= CC (C= 2 …